ABSTRACT
BACKGROUND: COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around the world. Although children, including children with cancer, have been found to be affected less commonly and less severely than adults, indirect effects of the pandemic on the diagnosis and treatment of children with cancer have been less described. METHODS: A survey was performed in the four largest tertiary pediatric hematology-oncology medical centers in Israel. Clinical and laboratory data were collected from the medical files of patients diagnosed or treated with cancer during April-October 2020. RESULTS: Seventeen patients are described, who had a significant delay in diagnosis or treatment of cancer. These represent approximately 10% of all pediatric cancer diagnosed during the study period in these centers. A main cause of delay was fear of exposure to COVID-19 (fears felt by the patient, parent, physician, or decision-makers at the institution; or the implementation of national guidelines). Delays also resulted from co-infection with COVID-19 and the attribution of the oncologic symptoms to the infection. In addition, treatment was delayed of patients already diagnosed with cancer, due to COVID-19 infection detected in the patient, a family member, or a bone marrow donor. CONCLUSION: Fear from the COVID-19 pandemic may result in delayed diagnosis and treatment of children with cancer, which may carry a risk to dismal prognosis. It is crucial that pediatricians and patients alike remember that other diseases still prevail and must be thought of and treated in a timely fashion.
ABSTRACT
Systemic doxorubicin is effective for desmoid fibromatosis (DF), but its use is limited by dose-dependent cardiotoxicity. A protocol of selective intra-arterial doxorubicin drug-eluting embolization (DEE) was designed to maximize target tissue efficacy of doxorubicin, while minimizing systemic exposure. Four children with recurrent or refractory DF were treated between 2014 and 2017. Tumor volumes were reduced by 54%-97% over a follow-up interval of 6-32 months. A single patient experienced transient lower extremity paresthesia (Common Terminology Criteria for Adverse Events grade I). Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment.
Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Chemoembolization, Therapeutic/methods , Doxorubicin/administration & dosage , Fibromatosis, Aggressive/drug therapy , Adolescent , Age Factors , Angiography , Antibiotics, Antineoplastic/adverse effects , Chemoembolization, Therapeutic/adverse effects , Child, Preschool , Cone-Beam Computed Tomography , Doxorubicin/adverse effects , Feasibility Studies , Female , Fibromatosis, Aggressive/diagnostic imaging , Fibromatosis, Aggressive/pathology , Humans , Magnetic Resonance Imaging , Male , Time Factors , Treatment Outcome , Tumor Burden/drug effectsABSTRACT
Children are growing people. When they are suffering from cancer, they are often malnourished. Their nutritional care must be adapted and form an integral part of the overall treatment. The diet of Léa, a young girl suffering from neuroblastoma, was enriched and adjusted in order to take into account the side effects of her treatment.
